Combined, our data support the development of a specific PLA2G16 inhibitor or alternative strategies, such as in vivo gene targeting of PLA2G16 by CRISPR/Cas9 technology, for the treatment of osteosarcomas. This evidence concerns the gene PLAAT3 and osteosarcoma.